Ypsomed Holding AG

Ypsomed Holding AG is a Swiss-based medical technology company recognized as a leading developer and manufacturer of injection and infusion systems for self-medication. Celebrating four decades of innovation, Ypsomed specializes in solutions for patients requiring regular administration of liquid medications, with a strong emphasis on diabetes care. The company’s portfolio includes products such as autoinjectors, insulin pumps, pen injectors, and a range of infusion systems, marketed under the "mylife Diabetescare" brand directly to patients, healthcare providers, and pharmacies. In addition to direct sales, Ypsomed serves pharmaceutical and biotechnology companies through its Ypsomed Delivery Systems business, offering device solutions and related services that enable convenient and reliable subcutaneous drug delivery. Headquartered in Burgdorf, Switzerland, Ypsomed operates globally with a network of production sites, subsidiaries, and distribution partners, and employs over 2,600 people. Its products play a vital role in the treatment and management of diabetes, infertility, growth disorders, and other clinical conditions, supporting both healthcare professionals and patients in achieving better therapeutic outcomes.